AI Article Synopsis
- Fidaxomicin is an antibiotic used to treat Clostridium difficile infections, primarily in severe cases or recurrences in the UK.
- In a study conducted at Queen Elizabeth Hospital Birmingham, 38 patients treated with fidaxomicin showed a 64% response rate for mild CDI during their first episode, but all patients with recurrent CDI were unsuccessful.
- The treatment was less effective for severe CDI, with only 42% responding, indicating that fidaxomicin is most effective for mild cases during the initial infection.
Article Abstract
Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jhin.2018.12.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!